New drug shows promise against deadly parasitic disease
NCT ID NCT05593666
First seen Jan 09, 2026 · Last updated May 08, 2026 · Updated 16 times
Summary
This study tested a new drug called LXE408 in 101 adults and teenagers with primary visceral leishmaniasis, a serious parasitic infection. The goal was to see if the drug could cure the infection by Day 28, meaning symptoms improved and no parasites were found in the spleen or bone marrow. The trial compared two different LXE408 treatment plans to each other and to a standard drug, AmBisome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY VISCERAL LEISHMANIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
DrugsNeglectedD Investigational Site
Bihār, India
-
DrugsNeglectedD Investigational Site
Patna, India
Conditions
Explore the condition pages connected to this study.